JAX-NYSCF Stem Cell Toolkit for Parkinson’s Disease
Backed by $6.4M in grants, the team will create and validate more than 20 patient-derived stem cell lines, then share the cells, protocols and data publicly.
iPSC/ESC
The latest induced, embryonic, and other pluripotent stem cell news.
iPSC-Derived Heart Cells Show Early Promise in Chinese Heart Failure Trial
HELP Therapeutics’ iPSC-derived cardiomyocytes improved walking distance, myocardial perfusion and heart wall thickening when added to bypass surgery in a 20-patient randomized trial.
Aspen Neuroscience Nabs FDA RMAT Designation for its Parkinson’s Cell Therapy
The designation gives Aspen added FDA support as it advances sasineprocel, a personalized autologous cell therapy for Parkinson’s disease, through clinical development.
Novo Nordisk Publishes Results from Embryonic Stem Cell-Derived Dopaminergic Cells for Parkinson’s Phase 1/2
The early trial, published in Nature, found that transplanting stem cell-derived dopaminergic progenitor cells into the brains of people with moderate Parkinson’s disease appeared feasible and showed a favorable 12-month safety profile,...
Kenai Therapeutics Completes Enrollment of Phase 1b/2a Parkinson’s iPSC Trial
The iPSC-derived neural cell therapy takes its next step in potentially restoring dopaminergic neurons lost to the condition.
Guts & Glory: Both of Cynata’s iPSC Trials Flop, GVH Phase 2 and KOA Phase 3
Sad day for the industry, here's a summary of the CEO/Executive Chairman's readouts of the trials.
Aspen Neuroscience Completes Cohort 3 and 4 Dosing in iPSC-Derived Phase 1/2a for Parkinson’s
The ASPIRO trial of sasineprocel is progressing; fifteen patients have been dosed with the commercial-ready formulation of the autologous cell therapy.
Heartseed Doses First Patient in Historic iPSC-Derived Cardiomyocyte Trial Via Catheter
The company's lead program, HS-001, required open heart surgery, while the new innovation allows for a much simpler, less invasive administration.
UniXell Biotechnology Nabs IND Clearance for its iPSC Parkinsons Therapy, UX-DA003
The Chinese company also received an IND in China a few weeks ago. Supported by good preclinical data, they'll advance clinical trials in both countries soon.
First Patient Dosed in Neural Stem Cell Therapy for Huntington’s Trial at UCI Health
The embryonic-derived cell therapy is implanted directly into the brain, and this early trial hopes to establish safety and baseline efficacy.